Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Radiation guidelines for proton therapy in mediastinal lymphoma

Dabaja BS et al. Blood. 2018 Oct 18;132(16):1635-46. http://www.bloodjournal.org/content/132/16/1635?sso-checked=true

Key clinical point: Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but only when it offers an advantage over intensity-modulated radiotherapy.

Major finding: Proton therapy reduces radiation dose to organs at risk in certain clinical presentations, such as when the mediastinal target is on both sides of the heart. The advantages are not always clear in other situations, such as when the target spans the right side of the heart, or when the target is above the heart with no axillary involvement.

Study details: New guidelines from the International Lymphoma Radiation Oncology Group on use of proton therapy in mediastinal lymphoma.

Disclosures: The guideline authors reported having no outside funding or conflicts of interest.

Read the article here.

Citation:

Dabaja BS et al. Blood. 2018 Oct 18;132(16):1635-46.

http://www.bloodjournal.org/content/132/16/1635?sso-checked=true

This Week's Must Reads

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

Must Reads in Aggressive Lymphomas

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6